Am­gen and No­var­tis back Aimovig with new da­ta as mi­graine com­pe­ti­tion heats up

Fac­ing a slew of com­peti­tors, Am­gen and No­var­tis are march­ing out new Phase IV re­sults to bol­ster Aimovig, their first-to-mar­ket CGRP in­hibitor for mi­graine pre­ven­tion.

The re­sults come about a year and a half af­ter the drug was panned by a group of med­ical ex­perts who con­vened at Unit­ed­Health Group’s Op­tum­Rx of­fices, con­clud­ing it and two oth­er drugs had no clear ben­e­fit over ex­ist­ing treat­ments. The pan­el sug­gest­ed that US in­sur­ers im­pose lim­its on its use, as well as Te­va’s Ajovy and Eli Lil­ly’s Em­gal­i­ty, all ap­proved in 2018, ac­cord­ing to a Reuters re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER